Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

Name: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Published: 2021
License: Public Domain

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

acute-myeloid-leukemia hematopoietic-stem-cell-transplantation

hematopoietic stem cell transplantation, acute graft versus host disease, acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

Related documents